Mirae Asset Global Investments
NRIX icon

Mirae Asset Global Investments’s Nurix Therapeutics NRIX Stock Holding History

Mirae Asset Global Investments’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Sell
4,625
-739
-14% -$12.6K ﹤0.01% 1217
2026
Q1 		$83.1K Buy
5,364
+438
+9% +$7.26K ﹤0.01% 1209
2025
Q4 		$93.4K Buy
4,926
+1,970
+67% +$28.3K ﹤0.01% 1274
2025
Q3 		$27.3K Buy
2,956
+11
+0.4% +$114 ﹤0.01% 1450
2025
Q2 		$33.5K Buy
2,945
+406
+16% +$4.39K ﹤0.01% 1313
2025
Q1 		$30.8K Buy
2,539
+178
+8% +$2.98K ﹤0.01% 1325
2024
Q4 		$45.1K Buy
2,361
+31
+1% +$711 ﹤0.01% 1278
2024
Q3 		$53.7K Buy
2,330
+559
+32% +$12.7K ﹤0.01% 1292
2024
Q2 		$36.7K Sell
1,771
-29,133
-94% -$454K ﹤0.01% 1298
2024
Q1 		$316K Buy
30,904
+6,628
+27% +$71.3K ﹤0.01% 2088
2023
Q4 		$251K Sell
24,276
-3,099
-11% -$21.2K ﹤0.01% 2269
2023
Q3 		$215K Sell
27,375
-676
-2% -$6.17K ﹤0.01% 2266
2023
Q2 		$280K Sell
28,051
-1,486
-5% -$15.2K ﹤0.01% 2207
2023
Q1 		$262K Buy
29,537
+5,279
+22% +$55K ﹤0.01% 2230
2022
Q4 		$266K Buy
24,258
+19
+0.1% +$229 ﹤0.01% 2202
2022
Q3 		$316K Buy
24,239
+14,141
+140% +$224K ﹤0.01% 2139
2022
Q2 		$128K Buy
+10,098
New +$114K ﹤0.01% 2264

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Mirae Asset Global Investments's NRIX Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Nurix Therapeutics (NRIX) stake by 14% in Q2 2026, selling an estimated $12.6K and leaving 4,625 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1217.

Mirae Asset Global Investments first reported a position in NRIX in Q2 2022 and has held it in 17 quarters since. The position peaked at $316K in Q3 2022. 64 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Mirae Asset Global Investments held 4,625 shares of Nurix Therapeutics worth $112K as of Q2 2026.
  • Mirae Asset Global Investments sold 739 Nurix Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Nurix Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1217 holding.
  • Mirae Asset Global Investments first reported a position in Nurix Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Mirae Asset Global Investments's Nurix Therapeutics position peaked at $316K in Q3 2022.
  • 64 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.